176 related articles for article (PubMed ID: 23753030)
1. High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program.
Intermesoli T; Rambaldi A; Rossi G; Delaini F; Romani C; Pogliani EM; Pagani C; Angelucci E; Terruzzi E; Levis A; Cassibba V; Mattei D; Gianfaldoni G; Scattolin AM; Di Bona E; Oldani E; Parolini M; Gökbuget N; Bassan R
Haematologica; 2013 Nov; 98(11):1718-25. PubMed ID: 23753030
[TBL] [Abstract][Full Text] [Related]
2. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.
Hoelzer D; Walewski J; Döhner H; Viardot A; Hiddemann W; Spiekermann K; Serve H; Dührsen U; Hüttmann A; Thiel E; Dengler J; Kneba M; Schaich M; Schmidt-Wolf IG; Beck J; Hertenstein B; Reichle A; Domanska-Czyz K; Fietkau R; Horst HA; Rieder H; Schwartz S; Burmeister T; Gökbuget N;
Blood; 2014 Dec; 124(26):3870-9. PubMed ID: 25359988
[TBL] [Abstract][Full Text] [Related]
3. Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.
Kasamon YL; Brodsky RA; Borowitz MJ; Ambinder RF; Crilley PA; Cho SY; Tsai HL; Smith BD; Gladstone DE; Carraway HE; Huff CA; Matsui WH; Bolaños-Meade J; Jones RJ; Swinnen LJ
Leuk Lymphoma; 2013 Mar; 54(3):483-90. PubMed ID: 22835045
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H
Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129
[TBL] [Abstract][Full Text] [Related]
5. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients.
Xicoy B; Ribera JM; Müller M; García O; Hoffmann C; Oriol A; Hentrich M; Grande C; Wasmuth JC; Esteve J; van Lunzen J; Del Potro E; Knechten H; Brunet S; Mayr C; Escoda L; Schommers P; Alonso N; Vall-Llovera F; Pérez M; Morgades M; González J; Fernández A; Thoden J; Gökbuget N; Hoelzer D; Fätkenheuer G; Wyen C;
Leuk Lymphoma; 2014 Oct; 55(10):2341-8. PubMed ID: 24397614
[TBL] [Abstract][Full Text] [Related]
6. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.
Rigaud C; Auperin A; Jourdain A; Haouy S; Couec ML; Aladjidi N; Gandemer V; Lambliotte A; Plat G; Landman-Parker J; Michon J; Leblanc T; Patte C; Minard-Colin V
Pediatr Blood Cancer; 2019 Sep; 66(9):e27873. PubMed ID: 31207026
[TBL] [Abstract][Full Text] [Related]
7. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
8. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
Fayad L; Thomas D; Romaguera J
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S57-62. PubMed ID: 18284717
[TBL] [Abstract][Full Text] [Related]
9. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.
Noy A; Lee JY; Cesarman E; Ambinder R; Baiocchi R; Reid E; Ratner L; Wagner-Johnston N; Kaplan L;
Blood; 2015 Jul; 126(2):160-6. PubMed ID: 25957391
[TBL] [Abstract][Full Text] [Related]
10. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.
Rizzieri DA; Johnson JL; Byrd JC; Lozanski G; Blum KA; Powell BL; Shea TC; Nattam S; Hoke E; Cheson BD; Larson RA;
Br J Haematol; 2014 Apr; 165(1):102-11. PubMed ID: 24428673
[TBL] [Abstract][Full Text] [Related]
11. Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab).
Ribera JM; García O; Grande C; Esteve J; Oriol A; Bergua J; González-Campos J; Vall-Llovera F; Tormo M; Hernández-Rivas JM; García D; Brunet S; Alonso N; Barba P; Miralles P; Llorente A; Montesinos P; Moreno MJ; Hernández-Rivas JÁ; Bernal T
Cancer; 2013 May; 119(9):1660-8. PubMed ID: 23361927
[TBL] [Abstract][Full Text] [Related]
12. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
13. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
Cortes J; Thomas D; Rios A; Koller C; O'Brien S; Jeha S; Faderl S; Kantarjian H
Cancer; 2002 Mar; 94(5):1492-9. PubMed ID: 11920506
[TBL] [Abstract][Full Text] [Related]
14. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
Roschewski M; Dunleavy K; Abramson JS; Powell BL; Link BK; Patel P; Bierman PJ; Jagadeesh D; Mitsuyasu RT; Peace D; Watson PR; Hanna WT; Melani C; Lucas AN; Steinberg SM; Pittaluga S; Jaffe ES; Friedberg JW; Kahl BS; Little RF; Bartlett NL; Fanale MA; Noy A; Wilson WH
J Clin Oncol; 2020 Aug; 38(22):2519-2529. PubMed ID: 32453640
[TBL] [Abstract][Full Text] [Related]
15. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
[TBL] [Abstract][Full Text] [Related]
16. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia.
Todeschini G; Bonifacio M; Tecchio C; Balter R; Carli G; Stefani PM; Adami F; Zamò A; Dei Tos AP; Marino F; Gherlinzoni F; Marradi P; Semenzato G; Pizzolo G
Am J Hematol; 2012 Jan; 87(1):22-5. PubMed ID: 22086870
[TBL] [Abstract][Full Text] [Related]
17. [Rituximab combined with short-course and intensive regimen for Burkitt leukemia: efficacy and safety analysis].
Li Y; Gong XY; Zhao XL; Wei H; Wang Y; Lin D; Zhou CL; Liu BC; Wang HJ; Li CW; Li QH; Gong BF; Liu YT; Wei SN; Zhang GJ; Mi YC; Wang JX; Liu KQ
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):502-505. PubMed ID: 32654465
[No Abstract] [Full Text] [Related]
18. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
[TBL] [Abstract][Full Text] [Related]
19. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
20. Improved outcome in adult B-cell acute lymphoblastic leukemia.
Hoelzer D; Ludwig WD; Thiel E; Gassmann W; Löffler H; Fonatsch C; Rieder H; Heil G; Heinze B; Arnold R; Hossfeld D; Büchner T; Koch P; Freund M; Hiddemann W; Maschmeyer G; Heyll A; Aul C; Faak T; Kuse R; Ittel TH; Gramatzki M; Diedrich H; Kolbe K; Fuhr HG; Fischer K; Schadeck-Gressel C; Weiss A; Strohscheer I; Metzner B; Fabry U; Gökbuget N; Völkers B; Messerer D; Uberla K
Blood; 1996 Jan; 87(2):495-508. PubMed ID: 8555471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
